Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 14, 2022 12:17pm
126 Views
Post# 34824447

RE:RE:RE:RE:RE:RE:RE:Questions

RE:RE:RE:RE:RE:RE:RE:Questions

You have to understand SD is a veryspecific description of how their tumours are responding not how they feel. It doesn't tell you anything about their general health. They may not have been experiencing this effect as any sort of improvement in the quality of their life. While SD is something for trial sponsors it might not match the expectations of the patient. 


SPCEO1 wrote: Based on what I have come to know about these trials, the human factor is a big deal. Like the person who just wanted to return to a normal life after 33 weeks on the trial. Rationally, that person would have stayed on the trial as long as possible but the effort involved and the many twists and turns this person likely had already faced can easily wipe you out both physically and emotionally. 

I suspect those 16 were a combination of the drug not having any impact (non-sortilin overexpressing tumors in the trial), death, exhaustion and a few at t he 420mg dose where the side efffects were an issue.  
 

qwerty22 wrote:

"I am not sure what you think is unclear."
 

I was trying to give my best answer to Palinc Q about whether we assume the other 16 did not survive long enough. That seems unclear. Christian gave a number of potential reasons why people might have dropped out. Sometimes contradictory (which doesn't matter too much in this context). It's unclear why people dropped out. Probably for a mix of reasons.
 





<< Previous
Bullboard Posts
Next >>